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Abstract
Background: The understanding of cutaneous pigmentation biology is relevant from the biologic
and clinical point of view. The binding of α-melanocortin and its specific receptor, on the plasma
membrane of melanin synthesising cells, plays a crucial role in melanins biosynthesis. Furthermore,
loss of MC1R function is associated with an increased incidence of melanoma and non-melanoma
skin cancer. The expression of the α-melanocortin receptor gene is highly controlled but, at the
present, region responsible for tissue-specific activity of the gene promoter has not been identified.
Methods: We have cloned the genomic sequences upstream the human MC1R coding gene. A
DNA fragment of 5 kilobases upstream the human MC1R encoding sequence was placed in front
of a reporter gene and several deletion mutants of such fragment have been prepared. These
constructs have been tested for the ability to drive the melanocyte-specific gene expression of the
reporter gene using transfection experiments in melanocyte and non-melanocyte cell lines. From
these experiments we identified a DNA fragment with the ability to drive the gene transcription in
a tissue-specific way and we used this small DNA fragment in DNA-protein interaction assays.
Results: We show that the 150 base pairs upstream the MC1R gene initiation codon are able to
drive the melanocyte-specific gene transcription. Furthermore, we provide experimental evidences
suggesting that on such minimal melanocyte-specific gene promoter can assemble tissue-specific
complexes.
Conclusion:  The present results strongly imply that the transcriptional regulation of the
melanocyte-specific MC1R gene requires an internal promoter located in the 150 base pairs
upstream the initiation codon.
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Background
Melanocytes and neuroblasts through melanogenesis and
catecholamine synthesis are capable of transforming the
same precursor L-tyrosine [1]. These two pathways are
potentially cytotoxic and mutagenic due to the produc-
tion of reactive oxygen species [2]. A crucial role in mela-
nins biosynthesis is played by the pro-opiomelanocortin
as well as by the melanocortin receptor 1 (MC1R), the pre-
cursor of the α-melanocortin (α-MSH) and its seven-
transmembrane G-protein coupled receptor, respectively
[3]. The α-MSH binding to MC1R increases the level of
cyclic AMP (cAMP) [4]. The adenylate cyclase pathway
induces the expression of the microphtalmia-associated
transcription factor (MITF), a member of the basic helix-
loop-helix (bHLH) transcription factors that through
binding to the E-box (CANNTG) on the gene promoters is
involved in the transcriptional regulation of several
melanocyte-specific genes such as tyrosinase, Tyrosinase
Related Protein-1 (TRP-1) and TRP-2 [5]. Therefore,
MC1R is a melanocyte differentiation marker which plays
a major role in the pigmentation process in mammals.
MC1R variants are also associated with increased risk of
malignant melanoma in a variety of populations [6,7],
MC1R gene product has been proposed as a new marker
and a putative therapeutic target for uveal melanoma [8].
Although fair skin is a well-known risk factor for skin can-
cer, most of the aforementioned studies conclude that
increased skin cancer susceptibility due to MC1R variation
cannot be explained solely on the basis of pigmentary
phenotype thus making the effects of the MC1R variants
on skin cancer risk unrelated [9].
Although MC1R has been detected in different cell line-
ages, it is mainly expressed in melanocytes. Its gene
expression is regulated at transcriptional, post-transcrip-
tional and translational levels by its agonist, α-MSH, and
the antagonists, agouti signal protein and agouti related
protein [10].
The MC1R gene promoter has been identified and the
minimal region exhibiting promoter activity has been
located between nucleotides -517 and -282 from the initi-
ation of translation [11]. Experimental evidences revealed
that the gene promoter includes several E boxes able to
bind both MITF and Upstream Stimulating Factor-1
[11,12]. It has been shown that MITF activates the MC1R
gene promoter in cultured mast cells and in co-transfec-
tion experiments in NIH3T3 cells [13,14], thus raising the
question about the melanocyte-specific expression of
MC1R. In this regard, Moro et al. have shown that the
minimal MC1R gene promoter displays the same activity
in receptor positive as well as negative cells [11]. This sug-
gests that the cis-acting region responsible for tissue-spe-
cific expression of the MC1R has not been jet identified.
In the present study we have addressed the identification
of the sequences, in the human MC1R gene promote,
which are involved in the melanocyte-specific expression.
We demonstrate that the minimal promoter with melano-
cyte-specific activity resides in the fragment of 150 base
pairs upstream of the start codon.
Methods
Genomic screening, cloning and deletion mutants
In order to identify the cosmid containing the MC1R gene
a pool of cosmids clones, containing a human genomic
library, were screened by PCR using the oligos 5'-atggctgt-
gcagggatcccagag-3' and 5'-gtgcaccggcctccagcaggaggatg-3'.
The library was obtained from the YAC Screening Center
(Milan, Italy). The selected cosmid was digested with
Mlu1 and BamH1 and the 5 kb fragment was cloned in
pGL3 Basic (Promega Madison WI USA) digested with
Mlu1 and Nco1. The BamH1 and the Nco1 sites were
blunted by fill-in reactions in presence of deoxinucle-
otides and the large Klenow fragment. The new construct,
pFull, was confirmed by restriction analysis and by direct
sequencing of the insert borders. pFull-A was generated
digesting pFull with Aat2 and self-ligation of the large
fragment. pFull-Bs derives from the self-ligation of the
large fragment generated by the pFull digestion with
BssH2. The construct pFull-MBs has been generated by the
self-ligation of the vector pFull digested with Mlu1 and
BssH2, both fragment ends were blunted by fill-in reac-
tions in presence of deoxinucleotides and the Klenow
enzyme. To generate pFull-Bg, the DNA fragment of about
1.8 kb obtained from pGL3 Basic digested with Bgl2 and
Xba1 was cloned in the vector obtained digesting pFull-
MBs with the same enzymes. pFull-MBg derives from the
self-ligation of the large fragment of pFull-MBs digested
with Bgl2 and Mlu1, both fragment ends were blunted by
fill-in reactions in presence of deoxinucleotides and the
large Klenow fragment. All the deletion mutants were con-
firmed by restriction analysis or by direct sequencing.
Cell lines and transfection experiments
The HeLa and NIH 3T3 cell lines, (kindly provided by Dr.
M. Alimandi) as well as the MeWo cell line were cultivated
in D-MEM (Invitrogen Life Technologies, Milan, Italy)
supplemented with 10% of foetal calf serum, 10 IU/ml of
penicillin and 10 μg/ml streptomycin at 37°C in humidi-
fied atmosphere of 5% CO2-95% air. The transfection
experiments were performed in 6 well vessels by Lipo-
fectamine 2000 reagent Invitrogen following the manu-
facturer instructions. The luciferase reporter vector used at
0.4 μg and 50 ng of the pCMV-β-galactosidase plasmid
were used to determine transfections efficiency. 48 hours
after transfections the cell extracts were prepared using the
Report Lysis Buffer (Promega, Milan Italy). The luciferase
and β-galactosidase assays were performed as previously
reported [15]. Transfection experiments were done in trip-Journal of Experimental & Clinical Cancer Research 2008, 27:71 http://www.jeccr.com/content/27/1/71
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licate and performed at least three times. For each experi-
ment the mean of three independent experiments is
reported. The statistical analysis, performed utilising the
raw data, of all transfection experiments resulted in P <
0.05. For each experiment, the t-test (the probability asso-
ciated with the t-test) was calculated versus the respective
control group.
Electrophoretic mobility shift assay (Band-shift) and run-
on experiments
The band-shift assays were performed using nuclear pro-
teins extracted from MeWo and from NIH3T3 cells. The
nuclear proteins were extracted according to Shapiro et al.
[16]. The DNA probe was prepared by PCR using the pFull
vector as template and the oligonucleotides 5'-agatct-
gggggtgcccagatggaagg-3' and 5'-agtcctgtccaggaagcaggaag-
gag-3'. The forward oligonucleotide was labelled with γ-
ATP 32P and T4 Polynuclotide kinase. The PCR amplicon
was run on 2% agarose gel, purified and electroeluted. The
DNA binding assays were assembled on ice in buffer D
(20 nM Tris/HCl pH 7.9, 80 mM NaCl, 0.1 mM EDTA, 1
mM DTT, 0.5 mM PMSF, 10% glycerol) with 4 μg polyd(I-
C) and with10 μg of the extracted proteins. The reaction
was started adding the 32P labelled DNA fragment. After
20 minutes at room temperature the reaction was loaded
onto a 4.5% polyacrylamide gel in 0.5× Tris/Borate/EDTA
buffer and elettrophoresed at 200 V for 4 hours at 4°C.
Preparation of nuclei and nuclear run-on assays were
done essentially as previously described [17]. Briefly,
nuclei were harvested from approximately 500000 cells
by gentle vortexing in 700 μl of ice-cold lysis buffer (10
mM NaCl, 3 mM MgCl2, 10 mM Tris-HCl at pH 7.4, 5 mM
dithiothreitol, 0.5% Nonidet P-40). Nuclei were pelleted
by centrifugation, and cytoplasmic RNA was isolated from
the supernatant by adding 2 volumes of guanidinium thi-
ocyanate buffer. The nuclei were resuspended in an equal
volume of storage buffer (40% glycerol, 50 mM Tris-HCl
at pH 8.5 mM MgCl2, 0.1 mM EDTA) and frozen at -80°C
until assayed. To label nascent transcripts, nuclei were
thawed on ice and incubated in 25 mM HEPES (pH 7.4),
2.5 mM MgCl2, 2.5 mM dithiothreitol, 75 mM KCl, and
5% glycerol in the presence of 0.35 mM each ATP, GTP,
CTP, and 0.4 μM UTP plus 200 μCi of α-UTP 32P (3000
Ci/mM, DuPont NEN, Boston MA USA) for 30 min at
30°C. The reaction was stopped by digestion with RNase-
free DNase I for 15 min at 37°C followed by digestion
with proteinase K in the presence of 0.1% SDS and extrac-
tion with phenol/chloroform. Nucleic acids were precipi-
tated with cold 10% trichloroacetic acid, sequentially
washed with 5% trichloroacetic acid and ethanol, and
resuspended in 10 mM Tris-HCl (pH 7.4), 1 mM EDTA,
and 0.5% SDS. Hybridization of run-on transcription
products was performed in hybridization buffer (0.5 M
phosphate buffer at pH 7.2, 3.5% SDS, 33% formamide,
1 mg/ml bovine serum albumin, 1 mM EDTA, 20 μg/ml
yeast tRNA) at 55°C overnight. Blots were washed to 0.2
× SET (1 × SET is 150 mM NaCl, 30 mM Tris-HCl, pH 7.8,
2 mM EDTA), 0.1% SDS at 55°C, and exposed in a Phos-
phorImager cassette. The membrane was scanned and
analyzed using the PhosphorImager system with the
ImageQuant software (Molecular Dynamics from Amer-
sham Biosciences Europe GmbH)
Results
MC1R promoter activity in melanocyte and non-
melanocyte cell lines
With the aim of identifying the minimal tissue-specific
promoter involved in the melanocyte-specific MC1R gene
transcription, we have transiently transfected the vector
pFull, containing the 5 kb fragment upstream the MC1R
encoding sequence, or the vectors containing the deletion
mutants shown in figure 1A. The experiments were per-
formed in human melanoma MeWo cell line, expressing
the MC1R, and in NIH 3T3 cells, a murine cell line of
fibroblasts not expressing the receptor. As further negative
cell line we have used the HeLa cell line. The results of the
transfection experiments are reported in figure 1B. It
shows that the construct with 5 kb of the genomic
sequence upstream of the MC1R gene, pFull, drives the
expression of the reporter gene much more efficiently in
melanocytes than in non-melanocyte cells. Similarly, the
constructs, pFull-A, pFull-Bs, pFullMBs and pFull-MBg
show a higher transcriptional rate in MeWo cells. At vari-
ance, the promoter in pFull-Bg vector shows, in both cell
lines, the same activity. The promoters in pFull-MBs and
pFull-Bg differ only for the 150 bp Bg. That are absent in
pFull-Bg. Consistently, the pFull-MBg vector containing
only the first 150 bp, although with weaker activity respect
to the promoter of pFull, is still tissue-specific. Hence, this
result suggests that the 150 bp upstream the coding gene
plays a crucial role in the melanocyte-specific regulation
of the MC1R gene promoter. In agreement with this result
we show that the promoter in pBig has about the same
activity in all three cell lines, figure 1B. The large fragment
of about 5 Kb but deleted of the first 150 bp, present in
pBig, drives the reporter gene transcription at similar lev-
els in NIH 3T3, Hela and in MeWo cell lines. As previously
described in "Materials and Methods", this large fragment,
-5 Kb/-150 bp, has been cloned in pGL3 Enhancer
(Promega), thus the luciferase gene is under the transcrip-
tional control of the SV40 enhancer, present in the vector,
and of the inserted DNA fragment. Therefore, as control of
pBig we have used pGL3 Control, where the transcrip-
tional activity of the luciferase gene is under the regulation
of both the SV40 Enhancer and SV40 Promoter. pBig and
pGL3 Control, show a comparable activity in the MC1R
positive and negative cell lines indicating, once again, that
the initial 150 bp are required for melanocyte-specific
transcription of the MC1R gene, figure 1B. Moreover, weJournal of Experimental & Clinical Cancer Research 2008, 27:71 http://www.jeccr.com/content/27/1/71
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Figure 1 (see legend on next page)
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show the melanocyte specificity of the previously
described promoters, Figure 2. For each promoter the
mean activity obtained in melanocytes was divided by the
mean activity obtained in NIH 3T3 fibroblasts. Therefore,
the MeWo/NIH value represents an index of the melano-
cyte-specificity. Both constructs with the promoters lack-
ing the first 150 bp, pFull-Bg and pBig, show a value close
to 1 indicating that their activity was similar in the two cell
lines. Therefore, the results shown in figure 1 and 2
strongly suggest that the 150 bp upstream of the MC1R
encoding gene are necessary for the melanocyte-specific
activity of the gene promoter. In order to demonstrate that
the preferential expression of pFull and of pFull-MBg in
melanocytes is regulated at transcriptional level, we have
performed run-on experiments in MeWo and NIH3T3
transfected cells, figure 3. We have transiently transfected
the two cell lines with pFull or with pFull-MBg or with
pGL3 Promoter and to normalize for transfection effi-
ciency with pCMV-Seap2 vector as well. After 48 hours, we
have measured the Seap activity in the medium and we
have purified the nuclei from the cells. In figure 3A we
show the run-on experiment. In figure 3C we report the
values of the Seap assays and in figure 2B we show the
run-on results. Since we have performed the run-on exper-
iments taking into account the transfection efficiency, the
results shown in figure 3B, directly indicates that the
reporter gene in pFull and in pFull-MBg is better tran-
scribed in MeWo rather than in NIH3T3 cells. Therefore,
the differential activity of the MC1R gene promoter, both
in pFull and in pFull-MBg, shown in figure 1 with tran-
sient transfection experiments is regulated at transcrip-
tional level.
Transfection experiments Figure 1 (see previous page)
Transfection experiments. Schematic representation of MC1R-Luciferase reporter constructs and corresponding activities 
after transfection into MeWo, NIH3T3 and HeLa cell lines. A. We schematically illustrate, as empty box, the MC1R promoters 
driving the luciferase gene shown as a black box. The arrow schematically represents the major start of transcription as we 
have determined it by primer extension experiments both in MeWo and in NIH3T3 cells transfected with the pFull vector 
(data not shown). It is worth to mention that this result is in agreement with the start of transcription of the human MC1R 
gene previously reported [4], [5]. M, A, Bs and Bg indicate the restriction enzymes Mlu1, Aat2, BssH2 and Bgl2, respectively. B. 
pFull and the described deletion mutants have been transfected in MeWo, NIH 3T3 and HeLa cell lines. The promoter activity 
in MeWo (black), NIH 3T3 (gray) and Hela (stripe) are reported as percentage of the SV40 promoter of pGL3 Promoter vec-
tor arbitrarily considered as 100. The pBig promoter activity has been compared with the pGL3 Control activity, and in this 
case the transcriptional activity of pGL3 Control was arbitrarily considered, in all cell lines, as 100. 
Melanocyte-specificity Figure 2
Melanocyte-specificity. Using the results shown in figure 1 we report an index of melanocyte-specificy. It has been obtained 
dividing the mean promoter activity obtained in MeWo by the mean promoter activity measured in NIH 3T3.
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Run-on experiment Figure 3
Run-on experiment. A. Dot blot. 1, 2 and 3 indicate the transfections with pFull-MBg, pFull and pGL3Promoter, respectively. 
In the experiments shown in lanes 1, 2 and 3, the nylon membrane has been spotted with 2 μg of pGL3Basic and in the exper-
iment shown in lane 4, it has been spotted 2 μg of pBluescript to measure the background of the hybridization with the labelled 
nuclei of the cell lines transfected with pGL3 Promoter. * indicates that the exposure time is of about 2 hours whereas in 1, 2 
and 4 the blots have been exposed over-night. B. Each dot blot has been counted in the β-counter and the cpm are reported. 
Bkg stays for background and indicates the cpm of the experiments shown in lane 4. C. As transfection normaliser we have co-
transfected, in all the experiments, 200 ng of pCMV-Seap2 vector. The Seap activity was measured with SEAP Reporter Gene 
Assay (Roche). Since the transfection efficiency in NIH3T3 is about three times higher than in MeWo cells (see the Seap2 activ-
ity in section C), we have used, in the run-on experiments, one third of the purified NIH3T3 nuclei and all the nuclei purified 
from MeWo. 
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Melanocyte-specific DNA-protein complex
To support the results obtained in transfection experi-
ments we have performed band-shift experiments using as
probe the 150 bp upstream the human MC1R coding
gene, the entire minimal promoter identified in the trans-
fection experiments shown in figure 1. Such a probe was
assembled, in a band-shift assay, with the nuclear proteins
extracted from NIH 3T3 cells or from MeWo cells. In fig-
ure 4A we show that, together with some similar com-
plexes, there are some complexes formed only with the
nuclear proteins from melanocytes. The most evident of
the melanocyte-specific complexes is indicated by the
arrowhead. Since MITF is a crucial element of the melano-
cyte-specific gene transcription and since it has been
shown that it activates the MC1R gene promoter we have
envisaged that MITF could be present in the melanocyte-
specific complex shown in figure 4A[18]. In figure 4B we
show that the melanocyte-specific complex assembled on
the minimal MC1R tissue-specific promoter is specifically
competed by the presence, in the assay, of the double
strand oligonucleotide containing the MITF binding
sequence derived from the tyrosinase promoter, on the
contrary the same amount of an unrelated oligonucle-
otide, k oligo, does not affect the complex. Therefore, this
result suggests that MIFT is present in the complex assem-
bled on the 150 bp DNA fragment containing, as shown
in figure 1, the minimal melanocyte-specific MC1R gene
promoter. Hence, with the band-shift assay, we have iden-
tified a melanocyte-specific complex assembled on the
same DNA fragment that in transfection experiments
shows a melanocyte-specific promoter activity.
Discussion
In this study we have identified in the 150 bp, upstream
the ATG codon of the MC1R gene, the cis signal conferring
to the minimal gene promoter the melanocyte-specific
Band-shift assay Figure 4
Band-shift assay. Characterization of the complexes assembled on the minimal melanocyte-specific MC1R gene promoter. 
The labeled DNA fragment was incubated with the nuclear proteins extracted from NIH3T3 or MeWo as indicated. The 
arrow indicates the most evident tissue-specific complex.
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Page 8 of 9
(page number not for citation purposes)
gene transcription. The characterization of the 5'-flanking
region of the human MC1R has been performed by Moro
et al. [11], they have analyzed about 3 kb of the human
genomic sequences upstream the MC1R start codon, from
-282 to -3200, and they have identified the minimal pro-
moter region between the nucleotides -517 and -282.
However, the activity of all the analyzed constructs
showed similar promoter activity in both MC1R express-
ing and non expressing cells. Therefore, we propose to
modify such a MCR1 gene promoter definition including
the 150 bp upstream the initiation codon. The human
MC1R gene shows multiple transcription initiation sites
dispersed over a region of about 600 nucleotides span-
ning from -344 to -936 [10,11]. Therefore, our results
identify the melanocyte-specific cis promoter region in
the DNA sequence for the 5' untranslated region [5'-UTR]
of the messenger RNA. The formation of tissue-specific
DNA-protein complexes down-stream of the initiation of
transcription has been already described. Besides the
internal promoters of the RNA polymerase III transcribed
genes and from complexes assembled on the enhancer
sequences that are often located at the 3' of the gene, sev-
eral RNA Polymerase II transcribed genes have cis ele-
ments located in the genomic region transcribed in the 5'-
UTR and described as internal promoter. The transcrip-
tion of macrophage IGF-I exon 1 is positively regulated by
the 5'-UTR region [19] and, similarly, the CD28 gene is
transcriptionally regulated by cis sequences located in the
first exon upstream of the initiation codon [20].
On the basis of the results of the transfection data a fur-
ther consideration can be made. The melanocyte-specific
expression of the MC1R gene might be achieved not only
by the positive activity of tissue-specific transcription fac-
tors, such as MITF [12], expressed in the pigmented cells
but also through DNA-protein complexes able to repress
transcription in non-melanocytes. In fact, in the transfec-
tion experiments in NIH 3T3 cells, the most significant
difference in promoters strength is the increased activity
of pFull-Bg. Therefore, the possibility that a repressing
complex has been removed by the deletion of the first 150
bp in pFull-Bg should be considered. Therefore, it is pos-
sible to envisage that in non-melanocyte cells a potential
repressor could bind in the first 150 bp. In this regard, it
is worth to note that the band-shift experiment shows sev-
eral NIH3T3 specific complexes as well. This strategy to
regulate tissue-specific gene expression would parallel the
regulation exerted by REST/NRSF in neuronal cells. The
main function of REST/NRSF in fact is to repress expres-
sion of some neuronal genes in non-neuronal cell types
and in neuronal progenitor cells [21].
Conclusion
Although the present findings obtained with transient
transfection experiments, need further analysis of the
transcription factors assembled on the MC1R gene pro-
moter, collectively they demonstrate that the transcrip-
tional regulation of the melanocyte-specific MC1R gene
requires an internal promoter located in the 150 bp
upstream the initiation codon.
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